The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

@article{Liang2009TheCO,
  title={The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer},
  author={Jun Liang and Tao Jiang and Ru-yong Yao and Zi-min Liu and Hong-ying Lv and Wei-wei Qi},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2009},
  volume={66},
  pages={493-500}
}
To evaluate the effect of excision repair cross-complementing group 1 (ERCC1) and X-ray cross-complementing group 1 (XRCC1) gene polymorphisms on treatment outcome in patients receiving oxaliplatin-based regimens for metastatic colorectal cancer. Hundred and thirteen patients with a diagnosis of metastatic colorectal cancer were treated with oxaliplatin-based chemotherapy. ERCC1 codon 118C/T and XRCC1 codon 399A/G polymorphisms were tested by real-time polymerase chain reaction (RT-PCR) method… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Pharmacologic resistance in colorectal cancer: a review.

Therapeutic advances in medical oncology • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 33 references

a case–control study in a Southern Italian population

G Improta, A Sgambato, +3 authors colorectal cancer
Anticancer Res 28(5B):2941–2946 500 Cancer Chemother Pharmacol • 2010
View 1 Excerpt

Platinum resistance: the role of DNA repair pathways.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…